CoChat

A retrospective chart review study to quantify the monthly medical resource use and costs of treating patients with treatment resistant depression in the United Kingdom

Open access
Denee, Tom, Ming, Timothy, Waller, John, Bailey, Tom, Rajkovic-Hooley, Olivera, Middleton-Dalby, Chloe, Le, Hoa H., Zhang, Qiaoyi, McCrone, Paul, Taylor, David · 2021 · Current Medical Research and Opinion

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index; 4 of the 20 sources its claims cite were checked for support.

Abstract

Introduction: Major depressive disorder (MDD) is a globally prevalent chronic psychiatric illness with a significant disease impact. As many as 30% of patients with MDD do not adequately respond to two therapies and are considered to be treatment resistant. This study aimed to quantify healthcare costs associated with treatment resistant depression (TRD) in the UK. Methods: A retrospective chart review of patients with TRD was conducted in primary and secondary care settings over a 2 year period. Data abstracted from medical records of patients included demographics, clinical characteristics and healthcare resource utilization (HCRU; number of consultations, use of Crisis Resolution and Home Treatment Teams [CRHTTs], non-drug and drug interventions, and hospitalizations). HCRU per patient per month (28 days) was calculated for three health states: major depressive episode (MDE), remission and recovery. Unit costs were from the British National Formulary (BNF) and the Personal Social Services Research Unit (PSSRU). Results: A total of 295 patients with TRD were recruited between January 2016 and May 2018. The mean age of the total sample was 43.3 years; 60.3% were female. Costs per patient, per 28 days, were highest in the MDE state, with the average cost (£992) mainly driven by consultations, non-drug treatment, hospitalizations and CRHTT, with a considerable fall in costs as patients moved into remission and subsequent recovery. Conclusion: The results suggest that antidepressant treatments for TRD that are more effective in reducing the time spent in an MDE health state, and helping patients achieve remission and recovery, are essential for reducing the overall HCRU and costs in patients with TRD. Cost of TRD in the UK Strengths and limitations of this study This observational study of TRD is the first to assess the HCRU impact associated with different predefined health states. Using retrospective data from both primary and secondary care physicians from regions across the UK ensures a representative real-world patient population. One limitation is that the selection of patients is based on criteria that define TRD that rely on physician judgement. Although the study captures direct HCRU costs, the indirect costs of lost productivity and care are not included in the overall burden. This study has defined the current clinical management of patients with TRD in the UK and provides an estimate of the associated HCRU and associated costs. © 2021 Johnson & Johnson. Published by Informa UK Limited, trading as Taylor & Francis Group.

Overview

CoChat Summary

TL;DR

This retrospective UK chart review of 295 patients with treatment-resistant depression found direct NHS costs per 28 days were highest during a major depressive episode (£992), falling to £254 in remission and £99 in recovery. The authors conclude that treatments more effective at shortening MDE and achieving remission/recovery would reduce healthcare resource use and costs.

Key findings

  • In 295 patients with TRD, mean age was 43.3 years and 60.3% were female; 30 psychiatrists and 9 GPs contributed data.
  • Mean HCRU cost per patient per 28 days was £992 in MDE, £254 in remission, and £99 in recovery; non-drug HCRU was £980, £164, and £84, respectively.
  • MDE cost drivers included CRHTT (£326 vs £18 in remission/recovery), hospitalizations (£380 vs £42 remission and £12 recovery), primary care visits (£52), and specialist visits (£11) per 28 days.
  • Drug treatment costs were relatively low and highest in remission (£107) versus MDE (£38) and recovery (£28); the discussion reports an annual cost for patients with TRD of approximately £11,900.

Methods

  • Retrospective chart review in UK primary and secondary care; patients classified as TRD by treating physicians in the index window 1 January 2016–31 May 2016, with data recorded for 2 years until 31 May 2018.
  • 30 psychiatrists and 9 GPs were recruited, each identifying up to 10 eligible patients, yielding 295 patients; HCRU data included consultations, CRHTT use, ED admissions, hospitalizations, antidepressants, other psychiatric medications, and non-drug treatments.
  • Descriptive statistics were performed in STATA version 15.0 with no formal hypothesis testing; costs per patient per 28 days were calculated for MDE, remission, and recovery using unit costs from the BNF and PSSRU.

Limitations

  • Paper-stated: TRD selection relies on physician judgement; indirect costs of lost productivity and informal care are not included; the design relies on physician accuracy in completing eCRFs; observational retrospective health-state determination may limit precision; selection bias is possible because patients visiting more often were more likely to be included; the sample is heterogeneous with wide result distributions.
  • Paper-stated: missing HCRU data items were set to zero to preserve sample sizes, and the authors acknowledge reported averages might underestimate actual resource utilization.
  • Evident from the text: no formal hypothesis testing was performed, so health-state cost differences are descriptive only.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1080/03007995.2020.1857580

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Image 1
CC-BY-NC-ND · From the PDF
Image 2
CC-BY-NC-ND · From the PDF
Image 3
CC-BY-NC-ND · From the PDF
Figure 1 Outcome definitions plotted against time in months.
Figure 1 Outcome definitions plotted against time in months.CC-BY-NC-ND · From the PDF
Image 5
CC-BY-NC-ND · From the PDF

Verification

Claims the paper makes

3 Valid · 0 Not valid · 14 Not checked · 59 Own results and interpretations

15 more claims

Create a free account to see all 76 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 31
  • Probably not a substantial claim. 29
  • The quote only partly states this claim. 2

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 36 references

Research works printed but not linked: 4

  1. NICE. National Institute for Health and Care Excellence: Clinical Guidelines. Depression in adults: recognition and management. London: National Institute for Health and Care Excellence (UK); 2009.
  2. Gartlehner G, Hansen RA, Morgan LC, et al. AHRQ comparative effectiveness reviews. second-generation antidepressants in the pharmacologic treatment of adult depression: an update of the 2007 comparative effectiveness review. Rockville (MD): Agency for Healthcare Research and Quality (US); 2011.
  3. EMA. Guideline on clinical investigation of medicinal products in the treatment of depression. European Medicines Agency; 2013.
  4. Curtis L. Unit costs of health and social care 2010. Canterbury (UK): Personal Social Services Research Unit, University of Kent; 2010.

Cited by

See all 12

Metadata

Authors
Denee, T., Ming, T., Waller, J., Bailey, T., Rajkovic-Hooley, O., Middleton-Dalby, C., Le, H. H., Zhang, Q., McCrone, P., & Taylor, D.
Affiliations
  • Janssen (United Kingdom) (GB)
  • Adelphi Group (United Kingdom) (GB)
  • Adelphi Real World
  • Janssen Scientific Affairs (United States) (US)
  • University of Greenwich (GB)
  • The Tavistock and Portman NHS Foundation Trust (GB)
Corresponding author
Zhang, Qiaoyi
Venue
Current Medical Research and Opinion
Published
2021-01-25
Volume
37
Issue
2
Pages
311-319
ISSN
  • 0300-7995 (ISSN-L)
  • 1473-4877
OpenAlex
W3110538873
Cited by
12
References
33
Citations by year
2026: 2 · 2025: 1 · 2024: 4 · 2023: 3 · 2022: 1 · 2021: 1
FWCI
0.75
Type
journal article
Language
en
Open access
Locations
  • Current Medical Research and Opinion (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
Janssen
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
Keywords
treatment-resistant depression, major depressive disorder, healthcare resource utilization, health care costs, major depressive episode, remission, recovery, hospitalization, antidepressant treatment, primary and secondary care
MeSH terms
Adolescent, Adult, Antidepressive Agents, Major Depressive Disorder, Female, United Kingdom, Hospitalization, Humans, Male, Middle Aged, Patient Acceptance of Health Care, Referral and Consultation, Retrospective Studies, Health Care Costs, Depressive Disorder, Treatment-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (prompt extract-v3).

A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A retrospective chart review study to quantify the monthly medical resource use and costs of treating patients with treatment resistant depression in the United Kingdom. https://app.cochat.ai/papers/10.1080/03007995.2020.1857580
The paper
Denee, T., Ming, T., Waller, J., Bailey, T., Rajkovic-Hooley, O., Middleton-Dalby, C., Le, H. H., Zhang, Q., McCrone, P., & Taylor, D. (2021). A retrospective chart review study to quantify the monthly medical resource use and costs of treating patients with treatment resistant depression in the United Kingdom. Current Medical Research and Opinion. https://doi.org/10.1080/03007995.2020.1857580

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.